Multiple Sclerosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Biogen, Immune Response BioPharma, ImCyse, Atara Biotherapeutics, Emerald Health Pharma, Sanofi

Posted on
by

Multiple Sclerosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Biogen, Immune Response BioPharma, ImCyse, Atara Biotherapeutics, Emerald Health Pharma, Sanofi
The Key Multiple Sclerosis Companies in the market include – Biogen, Immune Response BioPharma, ImCyse, Atara Biotherapeutics, Emerald Health Pharmaceuticals, Sanofi, RemeGen, Gossamer Bio, 4D Pharma, HuniLife Biotechnology, Anokion, GSK plc, GeNeuro, Immunic Therapeutics, Sanofi, Hoffman-La-Roche, and others.

 

DelveInsight’s “Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Multiple Sclerosis, historical and forecasted epidemiology as well as the Multiple Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Multiple Sclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Sclerosis Market Forecast

 

Some of the key facts of the Multiple Sclerosis Market Report:

  • The Multiple Sclerosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

  • In September 2025, Zydus Lifesciences announced on Thursday that its subsidiary has partnered with Netherlands-based Synthon BV to launch a generic drug for treating multiple sclerosis in the US. Zydus Lifesciences Global FZE has secured an exclusive licensing and supply agreement with Synthon BV for Ozanimod capsules, a generic version of ZEPOSIA, for the US market, according to a regulatory filing.

  • In Sepetmber 2025, A generic version of Zeposia (ozanimod), which has received tentative approval from the U.S. Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS), will be produced and supplied by the Netherlands-based Synthon. Tentative approval indicates that the generic version has met all FDA standards for safety, efficacy, and quality. However, it cannot be marketed yet due to existing patent protections or exclusivity rights held by the brand-name drug.

  • In September 2025, Sanofi’s journey to secure regulatory approval for its investigational multiple sclerosis drug has hit another setback, as the FDA has decided to delay its approval decision by three months. Tolebrutinib, a BTK inhibitor acquired by Sanofi through its $3.7 billion purchase of Principia Biopharma in 2021, had been on track for an FDA decision by September 28, following a priority review earlier this year. Sanofi is seeking approval for the drug to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow the accumulation of disability in adult patients, independent of relapse activity.

  • In June 2025, Ashvattha Therapeutics announced at the SNMMI Annual Meeting that its nanomedicines can be tailored to visualize neuroinflammation in patients with Multiple Sclerosis.

  • In June 2025, IASO Bio showcased encouraging results of Equecabtagene Autoleucel in Multiple Sclerosis patients from an IIT study during the 11th Congress of the EAN.

  • In June 2025, Telomir Pharmaceuticals announced that Telomir-1 resets the body’s epigenetic clock, reverses DNA methylation, and restores gene regulation in patients with Werner Syndrome.

  • In May 2025, TG Therapeutics announced upcoming data presentations on BRIUMVI for Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting.

  • In May 2025, Immunic announced its intention to continue developing vidofludimus calcium (IMU-838), its investigational therapy for multiple sclerosis (MS), despite the Phase II trial not achieving its primary endpoint. Initial findings from the ongoing CALLIPER study (NCT05054140) indicated a slight benefit in an exploratory MRI-based primary measure, with a 5% annualized reduction in brain volume loss compared to placebo.

  • In March 2025, The U.S. FDA has granted Priority Review to Sanofi’s regulatory application for tolebrutinib, based on favorable results from the Phase III HERCULES (NCT04411641), GEMINI 1 (NCT04410978), and GEMINI 2 (NCT04410991) trials. This submission aims to secure approval for treating non-relapsing secondary progressive multiple sclerosis (nrSPMS) and focuses on slowing disability progression not linked to relapse activity in adults.

  • In February 2025, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) announced the successful completion of its Phase 1 trial titled “A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants.” The final review by the Safety Review Committee (SRC) confirmed that Lucid-21-302 (Lucid-MS) was well-tolerated, with no safety issues or serious adverse events observed. Lucid-MS is a first-in-class, neuroprotective agent without immunomodulatory effects, currently in development for treating multiple sclerosis (MS).

  • In January 2025, Pheno Therapeutics secured clinical trial authorization (CTA) from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to begin testing its small-molecule therapy, PTD802. This approval allows the launch of the first-in-human trial for PTD802, a selective antagonist of G protein-coupled receptor 17 (GPR17), aimed at enhancing remyelination in individuals with neurological conditions, especially multiple sclerosis (MS).

  • In January 2025, Contineum Therapeutics, Inc. (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on novel treatments for neuroscience, inflammation, and immunology (NI&I) disorders, announced the successful completion of enrollment for its Phase 2 PIPE-307 VISTA trial. The study has enrolled 168 participants and is investigating PIPE-307, a potentially first-in-class M1 receptor antagonist, as a treatment option for relapsing-remitting multiple sclerosis (RRMS).

  • In 2023, there were 728,000 prevalent cases of multiple sclerosis in the US, and this number is projected to undergo significant changes by 2034.

  • In 2023, when the prevalent cases of multiple sclerosis in Germany were analyzed by gender, there were approximately 61,000 cases among males and 150,000 cases among females.

  • In the UK, when multiple sclerosis cases were categorized by phenotype, a significant difference was observed, with RRMS being more prevalent than Clinically Isolated Syndrome, SPMS, and PPMS. In 2023, around 80,000 major cases of multiple sclerosis were recorded under the RRMS subtype, and these numbers are anticipated to fluctuate further during the study period from 2020 to 2034.

  • In 2023, Japan recorded about 5,000 prevalent cases of multiple sclerosis, with expectations that these numbers will fluctuate further by 2034.

  • Key Multiple Sclerosis Companies: Biogen, Immune Response BioPharma, ImCyse, Atara Biotherapeutics, Emerald Health Pharmaceuticals, Sanofi, RemeGen, Gossamer Bio, 4D Pharma, HuniLife Biotechnology, Anokion, GSK plc, GeNeuro, Immunic Therapeutics, Sanofi, Hoffman-La-Roche, and others

  • Key Multiple Sclerosis Therapies: BIIB091, NeuroVax, IMCY-0141, ATA188, EHP-101, SAR441344, RC18, GB7208, MRx0002, HuL001, ANK-700, GSK3888130, Temelimab, IMU-838, Tolebrutinib, Fenebrutinib, and others

  • The Multiple Sclerosis epidemiology based on gender analyzed that in the United States, the prevalence of Multiple Sclerosis is higher in females as compared to males

  • The Multiple Sclerosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Sclerosis pipeline products will significantly revolutionize the Multiple Sclerosis market dynamics.

  • The Multiple Sclerosis treatment market looks promising as the market is emerging with newer acute treatments that have been designated by the FDA to treat Multiple Sclerosis. However, large multicenter trials are still necessary to examine the overarching patterns of Multiple Sclerosis and treatment response as a whole.

 

Multiple Sclerosis Overview

Multiple sclerosis (MS) is a chronic autoimmune disease where the immune system attacks the protective covering (myelin) of nerve fibers in the central nervous system (CNS). This damage disrupts communication between the brain and the rest of the body, leading to symptoms such as fatigue, muscle weakness, vision problems, and coordination issues. The exact cause of MS is unknown, but it is thought to involve a combination of genetic and environmental factors.

 

Get a Free sample for the Multiple Sclerosis Market Report:

https://www.delveinsight.com/report-store/multiple-sclerosis-market

 

Multiple Sclerosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Multiple Sclerosis Epidemiology Segmentation:

The Multiple Sclerosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Multiple Sclerosis

  • Prevalent Cases of Multiple Sclerosis by severity

  • Gender-specific Prevalence of Multiple Sclerosis

  • Diagnosed Cases of Episodic and Chronic Multiple Sclerosis

 

Download the report to understand which factors are driving Multiple Sclerosis epidemiology trends @ Multiple Sclerosis Epidemiology Forecast

 

Multiple Sclerosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Sclerosis market or expected to get launched during the study period. The analysis covers Multiple Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple Sclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Multiple Sclerosis Therapies and Key Companies

  • BIIB091: Biogen

  • NeuroVax: Immune Response BioPharma

  • IMCY-0141: ImCyse

  • ATA188: Atara Biotherapeutics

  • EHP-101: Emerald Health Pharmaceuticals

  • SAR441344: Sanofi

  • RC18: RemeGen

  • GB7208: Gossamer Bio

  • MRx0002: 4D Pharma

  • HuL001: HuniLife Biotechnology

  • ANK-700: Anokion

  • GSK3888130: GSK plc

  • Temelimab: GeNeuro

  • IMU-838: Immunic Therapeutics

  • Tolebrutinib: Sanofi

  • Fenebrutinib: Hoffman-La-Roche

 

Discover more about therapies set to grab major Multiple Sclerosis market share @ Multiple Sclerosis Treatment Market

 

Multiple Sclerosis Market Drivers

  • Increasing population with Multiple Sclerosis

  • Extensive approved therapies

  • Wide range of R&D pipeline

  • Increasing awareness

 

Multiple Sclerosis Market Barriers

  • High cost of drugs

  • High incidence of adverse events

  • Patent expiration

 

Scope of the Multiple Sclerosis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Multiple Sclerosis Companies: Biogen, Immune Response BioPharma, ImCyse, Atara Biotherapeutics, Emerald Health Pharmaceuticals, Sanofi, RemeGen, Gossamer Bio, 4D Pharma, HuniLife Biotechnology, Anokion, GSK plc, GeNeuro, Immunic Therapeutics, Sanofi, Hoffman-La-Roche, and others

  • Key Multiple Sclerosis Therapies: BIIB091, NeuroVax, IMCY-0141, ATA188, EHP-101, SAR441344, RC18, GB7208, MRx0002, HuL001, ANK-700, GSK3888130, Temelimab, IMU-838, Tolebrutinib, Fenebrutinib, and others

  • Multiple Sclerosis Therapeutic Assessment: Multiple Sclerosis current marketed and Multiple Sclerosis emerging therapies

  • Multiple Sclerosis Market Dynamics: Multiple Sclerosis market drivers and Multiple Sclerosis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Multiple Sclerosis Unmet Needs, KOL’s views, Analyst’s views, Multiple Sclerosis Market Access and Reimbursement

 

To know more about Multiple Sclerosis companies working in the treatment market, visit @ Multiple Sclerosis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Multiple Sclerosis Market Report Introduction

2. Executive Summary for Multiple Sclerosis

3. SWOT analysis of Multiple Sclerosis

4. Multiple Sclerosis Patient Share (%) Overview at a Glance

5. Multiple Sclerosis Market Overview at a Glance

6. Multiple Sclerosis Disease Background and Overview

7. Multiple Sclerosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Multiple Sclerosis

9. Multiple Sclerosis Current Treatment and Medical Practices

10. Multiple Sclerosis Unmet Needs

11. Multiple Sclerosis Emerging Therapies

12. Multiple Sclerosis Market Outlook

13. Country-Wise Multiple Sclerosis Market Analysis (2020–2034)

14. Multiple Sclerosis Market Access and Reimbursement of Therapies

15. Multiple Sclerosis Market Drivers

16. Multiple Sclerosis Market Barriers

17. Multiple Sclerosis Appendix

18. Multiple Sclerosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/